In China, doctors are treating more and more cancer patients with the gene-editing tool known as CRISPR. But research on the technique is still limited.
Mad About Venture Capital
When you hear the phrase “venture capital,” what’s your reaction? Be honest. For most of us, visions of high-tech firms, Aaron Sorkin-esque walk and talks and huge piles of stock options pop into our heads.
Reality, though, is a lot different. We take a visit to Venture Madness in Scottsdale and talk to angel investor Jim Goulka.